Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children
-
- STATUS
- Recruiting
-
- participants needed
- 8000
-
- sponsor
- University of Zurich
Summary
There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists.
The main purpose of this study is to measure antibodies to SARS-CoV-2, symptoms, and risk factors in a representative cohort of children and adolescents in the canton of Zurich, Switzerland, shortly after re-opening of the school system and thereafter. The study also investigates antibodies to SARS-CoV-2 in parents of the children and school personnel.
Description
The role of children and adolescents in the transmission of SARS-CoV-2 remains highly unclear
and has been a key question since the early days of the pandemic. It has important
consequences for policy decisions, especially concerning the opening of the schools, sport
facilities and intergenerational contacts. However, the information on true
This study builds up a system to monitor the seroprevalence of SARS-CoV-2 in children and
adolescents who attend school in the canton of Zrich, Switzerland. The investigators aim to
assess children of randomly selected primary and secondary schools during the first weeks of
re-entering school from all districts of the canton of Zurich in June and July 2020, after
the temporary closure due to
In addition, the seroprevalence of SARS-CoV-2 in the parents of the participating children will be tested in August/September 2020, to examine clusters of infections in households. Seroprevalence of SARS-CoV-2 in school personnel will be tested in August/September 2020 and subsequently in October/November 2020 and February/March 2021, to examine temporal changes in the seroprevalences in the whole school community.
This study complements the ongoing coordinated efforts of seroprevalence studies in adults in Switzerland, through the Swiss School of Public Health (SSPH+) coordinated CORONA IMMUNITAS studies.
Details
Condition | Covid 19, SARS-CoV 2 |
---|---|
Age | 5years - 100years |
Treatment |
|
Clinical Study Identifier | NCT04448717 |
Sponsor | University of Zurich |
Last Modified on | 19 February 2024 |
How to participate?
,
You are contacting
Susi Kriemler, Dr.med.
Primary Contact
Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich
Switzerland
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
- 0
- 19 Feb, 2024
- 1 site
- 0
- 19 Feb, 2024
- 7 sites
- 0
- 19 Feb, 2024
- 1 site
- 0
- 19 Feb, 2024
- 1 site
- 0
- 19 Feb, 2024
- 1 site
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy AnnotationsStudy Notes
Enable the functional cookies in order to view/reply the sharedadd your annotations.
Add a private note
- Select a piece of text from the left.
- Add notes visible only to you.
- Send it to people through a passcode protected link.
Publish Annotation
Are you sure you want to publish the annotation?
Delete AnnotationNote
Are you sure you want to delete the annotationnote?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.